Is it safe to use losartan in patients with chronic kidney disease (CKD)?

Yes, losartan is safe and appropriate to use in patients with CKD

Losartan is recommended for patients with CKD, particularly those with albuminuria, and can be safely used across most stages of kidney disease without dose adjustment. 1, 2

Key Recommendations by CKD Stage and Albuminuria Status

Strongly Recommended (Class 1 Evidence)

• CKD with severely increased albuminuria (A3): Start losartan or another ARB regardless of diabetes status 1, 2
• CKD with moderately-to-severely increased albuminuria (A2-A3) AND diabetes: Start losartan or another ARB 1, 2

Suggested (Class 2 Evidence)

• CKD with moderately increased albuminuria (A2) without diabetes: Consider starting losartan 1, 2
• CKD without albuminuria (A1): May use losartan for other indications like hypertension or heart failure 1

Dosing Across CKD Stages

No dose adjustment is required for losartan in renal impairment unless the patient is also volume depleted 3. The standard dosing remains:

• Starting dose: 50 mg once daily
• Maximum dose: 100 mg once daily 4, 5, 6

Exception: Start at 25 mg daily only if the patient has hepatic impairment or is volume/salt depleted 3

Critical Monitoring Requirements

Check within 2-4 weeks of starting or dose increase 1, 2:

• Serum creatinine
• Serum potassium
• Blood pressure

When to Continue Despite Changes

Continue losartan unless 1, 2:

• Serum creatinine rises >30% within 4 weeks
• Symptomatic hypotension occurs
• Uncontrolled hyperkalemia persists despite treatment
• Patient develops angioedema

Managing Hyperkalemia

Do not automatically stop losartan for hyperkalemia 1, 2. First attempt:

• Dietary potassium restriction (note: high potassium intake may reduce antiproteinuric effect 7)
• Diuretic therapy
• Sodium bicarbonate if metabolic acidosis present
• Gastrointestinal cation exchangers

Advanced CKD Considerations

Continue losartan even when eGFR falls below 30 mL/min/1.73 m² 1. The renoprotective benefits persist in advanced CKD 8, 9, 10.

For patients on hemodialysis: Losartan remains effective and well-tolerated 10. No dose adjustment needed 3.

Evidence of Renoprotection

Multiple studies demonstrate losartan's renoprotective effects in CKD:

• Reduces proteinuria by 20-48% independent of blood pressure reduction 8, 9, 11
• Stabilizes eGFR progression 8
• Effective across all CKD stages including stage 3 8
• Benefits seen even in normotensive patients 8

Important Contraindications and Cautions

Absolute contraindications 4, 5, 6, 3:

• Pregnancy (discontinue immediately if detected)
• History of angioedema with ARBs
• Combination with ACE inhibitors, other ARBs, or direct renin inhibitors

Relative cautions 3:

• Bilateral renal artery stenosis (risk of acute renal failure)
• Severe volume depletion (correct first)
• Suspected functional renal artery stenosis 12

Common Pitfalls to Avoid

1. Don't discontinue prematurely for mild creatinine elevation: Up to 30% increase is acceptable and expected 1, 2

2. Don't withhold in advanced CKD: The drug remains beneficial even at eGFR <30 mL/min/1.73 m² 1

3. Don't combine with ACE inhibitors: This combination is potentially harmful and provides no additional benefit 4, 5, 6

4. Don't forget to temporarily suspend during acute illness: Hold during intercurrent illness, IV contrast administration, bowel prep, or major surgery 12

5. Monitor potassium intake: High dietary potassium may diminish the antiproteinuric effect during habitual sodium intake 7